Print Version
MMWR: Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations--United States, 2001
Author:
Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR
Publication Date:
2001
Country of Origin:
United States
Format:
Report
Language:
English
Abstract
This report provides preliminary information about 21 cases of liver injury associated with rifampin-pyrazinamide (RIF-PZA) and the revised recommendations on selecting appropriate therapy for patients with latent TB infection and monitoring the use of RIF-PZA to treat infection.Publisher:
Centers for Disease Control and Prevention (CDC)
Audience(s):
Health Professionals
Topic:
Treatment- Adverse Reactions, Case Management, Treatment Guidelines Materials, Treatment - Latent TB infection (Inactive TB), Treatment- Medication Information
Notes:
Massachusetts Medical Society: paper copies of single issues cost $5.25.
Disclaimer: The information on the Find TB Resources Website is made available as a public service. Neither the Centers for Disease Control and Prevention nor the National Prevention Information Network endorses the organizations, Website s, and materials presented. It is the responsibility of the user to evaluate this information prior to use based on individual, community, and organizational needs and standards.